Bambusa Initiates Subcutaneous BBT001 Dosing in Atopic Dermatitis
Bambusa Therapeutics has initiated subcutaneous dosing of BBT001 in atopic dermatitis, transitioning from an intravenous proof-of-concept phase the sponsor called 'compelling.'
Topic
Bbt001
Topic
Bbt001
Bambusa Moves BBT001 Into Subcutaneous Dosing in Atopic Dermatitis
Bambusa Therapeutics has started subcutaneous dosing of BBT001 in atopic dermatitis, advancing the program after compelling intra…